Convalescent Plasma as Treatment for Hospitalized Subjects With COVID-19 Infection

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2020
* This is a single arm phase IIa study of convalescent plasma for the treatment of individuals hospitalized with COVID-19 infection. * Subjects will be considered as having completed the study after 60 (+/- 3) days, unless consent withdrawal or death occurs first. * Interim analysis will be permitted as described in the statistical section 8. * The final analysis will be conducted once the last subject completes the day 60 visit or withdraws from the study.
Epistemonikos ID: 0224ab2c8d09600d1fc211448148f51d594a5b35
First added on: Apr 14, 2020